Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Apogee Therapeutics ( (APGE) ) has provided an update.
On April 21, 2026, Apogee Therapeutics, Inc. announced that board members Andrew Gottesdiener, M.D., and Peter Harwin had notified the company of their intention to resign from its Board of Directors effective May 11, 2026. The company stated that the departures, which were not due to any disagreements over operations, policies or practices, will reduce the size of the board from nine to seven directors, signaling a streamlined governance structure for the biopharmaceutical firm.
The most recent analyst rating on (APGE) stock is a Buy with a $118.00 price target. To see the full list of analyst forecasts on Apogee Therapeutics stock, see the APGE Stock Forecast page.
Spark’s Take on APGE Stock
According to Spark, TipRanks’ AI Analyst, APGE is a Neutral.
The score is held back mainly by pre-revenue status and escalating losses/cash burn, partially offset by a strong, low-leverage balance sheet and a major liquidity boost from the recent equity raise. Technicals are supportive with the stock trading above key moving averages, and corporate events are favorable due to positive clinical readouts.
To see Spark’s full report on APGE stock, click here.
More about Apogee Therapeutics
Apogee Therapeutics, Inc. is a biopharmaceutical company focused on developing therapeutic products, operating under the oversight of a corporate board of directors that guides its strategic direction and governance.
Average Trading Volume: 970,157
Technical Sentiment Signal: Buy
Current Market Cap: $6.13B
For a thorough assessment of APGE stock, go to TipRanks’ Stock Analysis page.